Adrenomedullin Antagonist Nanoparticles Inhibit Breast Cancer Brain Metastasis by Immunomodulating Monocytes/Macrophages
Breast cancer brain metastasis (BCBM) is a devastating disease with limited treatment options, largely due to the presence of the blood-brain barrier (BBB) in the central nervous system (CNS), and thus, the development of effective alternative therapies for BCBM remains a significant unmet clinical challenge. Herein, we found that monocytes, M2 macrophages, and adrenomedullin (AM) were abundantly present in human BCBM. Therefore, we innovatively proposed monocytes/macrophages as promising immunomodulatory targets for effective immunotherapy of BCBM in mice models. The high-density lipoprotein-mimicking peptide-phospholipid scaffold (HPPS) nanoparticle efficiently targets monocytes/macrophages. Meanwhile, the adrenomedullin antagonist (AMA)-carrying HPPS (AMA-HPPS) nanoparticle has the potential to target and immunomodulate monocytes/macrophages into antitumor effector cells due to the pro-inflammatory polarization ability of AMA. Given this, AMA-HPPS effectively targeted and modulated circulating monocytes after intravenous injection, enabling the delivery of nanoparticle to brain metastasis sites. Incorporating immunomodulatory CpG into AMA-HPPS (forming AMA-HPPS-CpG) further enhanced monocyte targeting and immunomodulation. Thus, AMA-HPPS-CpG further inhibited the BCBM and prolonged the survival of mice by modulating the differentiation of infiltrating monocytes/macrophages into M1 macrophages and promoting the infiltration of CD8<sup>+</sup> T cells into the brain. This effect was attributed to the activation of the NF-κB pathway in monocytes/macrophages following the uptake of nanoparticles, which reprogrammed the immunosuppressive tumor microenvironment. Therefore, this study highlights a promising immunotherapy strategy for brain metastasis by AMA-HPPS nanodrugs eliciting the pro-inflammatory polarization of monocytes/macrophages that have infiltrated the CNS as effector cells rather than considering monocytes/macrophages merely as a drug delivery system across the BBB.
Authors
- Xingxing Yu (ORCID: https://orcid.org/0009-0003-6366-5886)
- J Chen
- Yi Zhao (ORCID: https://orcid.org/0000-0001-9614-8509)
- Zhihong Zhang (ORCID: https://orcid.org/0000-0002-9771-1313)
- Yanfeng Dai (ORCID: https://orcid.org/0000-0003-3648-9429)
- Xuenan Yuan
- Gehao Chen
- Y. Q. Liu
- Wei J. Wang (ORCID: https://orcid.org/0000-0002-4848-7394)
- Yu Shi
- Mianfu Cao
Institutions
- University Health Network (CA)
- Army Medical University (CN)
- Hainan University (CN)
- Princess Margaret Cancer Centre (CA)
- Yangon University of Economics (MM)
- Applied Photonics (United Kingdom) (GB)
- Wuhan National Laboratory for Optoelectronics (CN)
- Health & Life (Taiwan) (TW)
- Huazhong University of Science and Technology (CN)
Publication Details
- Journal
- ACS Nano
- Published
- 2026-03-17
- DOI
- https://doi.org/10.1021/acsnano.5c15040
- Primary Topic
- Cancer, Stress, Anesthesia, and Immune Response
- Type
- article
- Field-Weighted Citation Impact
- 0.00